Back to Search
Start Over
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Source :
-
New England Journal of Medicine . 9/26/2024, Vol. 391 Issue 12, p1159-1161. 3p. - Publication Year :
- 2024
-
Abstract
- The document titled "Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma" presents the findings of two phase 3 trials that investigated the use of zolbetuximab, an IgGl monoclonal antibody, in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma. The results showed that when combined with first-line chemotherapy, zolbetuximab led to significantly longer progression-free survival and overall survival compared to placebo plus chemotherapy. This treatment was particularly effective for patients with HER2-negative tumors that were positive for claudin 18.2. The study provides valuable information for clinicians and researchers in the field of gastric cancer treatment. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00284793
- Volume :
- 391
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 180130218
- Full Text :
- https://doi.org/10.1056/NEJMc2409512